Want real case studies? 10 seconds to sign up
Join the platform
March 25, 2026
Approximately 5 minutes
Need Regulatory Help? Try Our Platform
Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.
Registered Pharmacist · AI Engineer · Director, ElendiLabs
Registered pharmacist, AI engineer, HKHAIS founder, and pharmaceutical & medical device SEO/GEO specialist.
Ask Anything
We'll follow up with you personally.
100% response rate • Reply within 7 business days
Related Articles
Approximately 5 minutes
Applying for a UK Marketing Authorisation for Medicines
The Medicines and Healthcare products Regulatory Agency (MHRA) requires companies to obtain a Marketing Authorisation (MA) before selling prescription or over-the-counter medicines in the UK, following national, decentralised, mutual recognition, or centralised procedures, with specific pathways for generics, biosimilars, and novel drugs.
Approximately 5 minutes
UK Guidance on Labelling for Clinical Trial Medicines
MHRA provides guidance on labelling investigational medicinal products (IMPs) for clinical trials, including requirements for unauthorised and authorised products, exemptions, blinding considerations, and decentralised manufacturing, in line with the Medicines for Human Use (Clinical Trials) Regulations.
Approximately 5 minutes
UK Clinical Trials Regulations Transitional Arrangements
The MHRA outlines transitional arrangements for clinical trials under the amended Medicines for Human Use (Clinical Trials) Regulations, effective 28 April 2026, distinguishing 'old rules' and 'new rules' trials, with specific provisions for approvals, transparency, GCP, pharmacovigilance, IMP manufacturing, labelling, and enforcement.
Approximately 5 minutes
Modifying Clinical Trial Approvals for Medicines in the UK
MHRA provides guidance on modifying clinical trial approvals for medicines, categorizing modifications as substantial (Route A or B), important detail, or minor, with processes for submission via IRAS, validation, review timelines, fees, and examples.
Approximately 5 minutes
Mastering Global MedTech Access: A Technical Roadmap Across Six Strategic Jurisdictions in 2026
An in-depth technical analysis of the 2026 global regulatory landscape, examining the transition from the gatekeeper model to Continuous Lifecycle Compliance across the EU, UK, Mexico, India, Indonesia, and Malaysia.
Approximately 5 minutes
Regulatory Divergence in European MedTech: EU MDR and UK MHRA Compared
An academic comparison of post-Brexit medical device regulations between the EU and the UK, highlighting compliance timelines, data requirements, and market access pathways.